Donald J. Hayden Jr - Jun 13, 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role
Director
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Stock symbol
THRX
Transactions as of
Jun 13, 2023
Transactions value $
$0
Form type
4
Date filed
6/13/2023, 05:29 PM
Previous filing
Jan 3, 2023
Next filing
Feb 14, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Stock Option (right to buy) Award $0 +19.5K $0.00 19.5K Jun 13, 2023 Common Stock 19.5K $9.61 Direct F1
transaction THRX Restricted Stock Unit Award $0 +3.25K $0.00 3.25K Jun 13, 2023 Common Stock 3.25K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Donald J. Hayden Jr is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The options are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001 per share, when vested.
F3 The RSUs are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. The RSUs have no expiration date.